Vireo Growth (VREOF) Cash from Operations Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.53 Bn | 23.47 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.32 Bn | 18.52 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 450.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 450.00% |
| Dec 31, 2025 | 389.54% |
| Sep 30, 2025 | -162.13% |
| Jun 30, 2025 | -49,694.90% |
| Mar 31, 2025 | -185.63% |
| Dec 31, 2024 | -1,302.11% |
| Sep 30, 2024 | -256.57% |
| Jun 30, 2024 | -100.58% |
| Mar 31, 2024 | 68.63% |
| Dec 31, 2023 | 92.49% |
| Sep 30, 2023 | 178.57% |
| Jun 30, 2023 | 152.92% |
| Mar 31, 2023 | 43.87% |
| Dec 31, 2022 | 21.51% |
| Sep 30, 2022 | 59.72% |
| Jun 30, 2022 | 75.34% |
| Mar 31, 2022 | -35.90% |
| Dec 31, 2021 | -12,398.11% |
| Sep 30, 2021 | -49.18% |
| Jun 30, 2021 | -163.16% |